Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy

Mayako Uchida, Saeko Murata, Hanae Morikawa, Hiroko Yonemitsu, Shigeru Ishida, Kimitaka Suetsugu, Toshikazu Tsuji, Hiroyuki Watanabe, Takehiro Kawashiri, Koji Kato, Keiko Hosohata, Toshihiro Miyamoto, Nobuaki Egashira, Tsutomu Nakamura, Koichi Akashi, Ichiro Ieiri

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND/AIM: The occurrence of chemotherapy-related serious adverse events (AEs) is associated with a poor prognosis of hematopoietic malignancies. We have developed a medication guidance sheet (MGS) for monitoring AEs occurring when combining chemotherapy with etoposide, methylprednisolone, cisplatin, cytarabine, and rituximab (ESHAP±R). In this study, the usefulness of MGS was investigated in non-Hodgkin's lymphoma patients.

PATIENTS AND METHODS: The MGS was used to monitor AEs in 48 adult patients receiving ESHAP±R. The prediction accuracy of the MGS was estimated before and after modification based on practical data.

RESULTS: A total of 246 AEs developed, all of which were predicted by the MGS. Among them, 149 events (61%) occurred during the same period as those predicted by the MGS. After modification of MGS for the onset and duration of AEs, the accuracy increased to 84%.

CONCLUSION: The accuracy of the original MGS for ESHAP±R was insufficient but greatly improved after the AEs duration modification.

Original languageEnglish
Pages (from-to)2053-2060
Number of pages8
JournalAnticancer research
Volume42
Issue number4
DOIs
Publication statusPublished - Apr 2022

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy'. Together they form a unique fingerprint.

Cite this